Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance
- 1 November 1991
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 28 (6) , 461-464
- https://doi.org/10.1007/bf00685823
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- DNA TOPOISOMERASE POISONS AS ANTITUMOR DRUGSAnnual Review of Biochemistry, 1989
- Biochemical basis for the interactions of type I and type II topoisomerases with DNAPharmacology & Therapeutics, 1989
- Inhibition of type II topoisomerase by fostriecinBiochemical Pharmacology, 1988
- Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26Biochemistry, 1988
- Multidrug Resistance1JNCI Journal of the National Cancer Institute, 1988
- In Vitro activity of the novel antitumor antibiotic fostriecin (CI-920) in a human tumor cloning assayEuropean Journal of Cancer and Clinical Oncology, 1986
- DNA TOPOISOMERASESAnnual Review of Biochemistry, 1985
- DNA topoisomerase II is required at the time of mitosis in yeastCell, 1985
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingAnalytical Biochemistry, 1976
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976